Provided by Tiger Trade Technology Pte. Ltd.

PMV Pharmaceuticals

1.44
+0.06504.73%
Post-market: 1.440.00000.00%16:10 EDT
Volume:673.56K
Turnover:951.89K
Market Cap:108.74M
PE:-1.02
High:1.45
Open:1.34
Low:1.34
Close:1.38
52wk High:1.88
52wk Low:1.02
Shares:75.51M
Float Shares:68.38M
Volume Ratio:0.99
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4131
EPS(LYR):-1.4800
ROE:-70.93%
ROA:-42.39%
PB:1.52
PE(LYR):-0.97

Loading ...

PMV Pharmaceuticals appoints Philip Herman as chief commercial officer

TIPRANKS
·
Sep 08

Press Release: PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

Dow Jones
·
Sep 08

PMV Pharmaceuticals Price Target Maintained with a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 04

PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering

TIPRANKS
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Craig-Hallum Sticks to Their Buy Rating for PMV Pharmaceuticals (PMVP)

TIPRANKS
·
Sep 01

U.S. Stocks on the MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics

Reuters
·
Sep 01

Top Premarket Decliners

MT Newswires Live
·
Sep 01

Oncology Firm PMV Pharma Falls on $51 Mln Stock-and-Warrants Sale

Reuters
·
Sep 01

PMV Pharmaceuticals 42M share Spot Secondary priced at $1.21

TIPRANKS
·
Sep 01

Press Release: PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

Dow Jones
·
Sep 01

PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering

MT Newswires Live
·
Sep 01

PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data

TIPRANKS
·
Sep 01

Oncology Co PMV Pharma Drops After Beginning Equity Offering

Reuters
·
Sep 01

PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial

TIPRANKS
·
Sep 01

PMV Pharmaceuticals announces common stock, warrants offering

TIPRANKS
·
Sep 01

PMV Pharma Launches Underwritten Public Offering of Common Stock, Warrants

Reuters
·
Sep 01

PMV Pharma Announces Proposed Public Offering of Securities

THOMSON REUTERS
·
Sep 01

PMV Pharma Says Rezatapopt Posts 46% Response Rate in Phase 2 Platinum-Resistant Ovarian Cancer Trial

Reuters
·
Sep 01

PMV Pharmaceuticals, - Median Time to Response 1.3 Months, Median Duration of Response 10.0 Months

THOMSON REUTERS
·
Sep 01